At least 70% of the Fund is invested in shares of companies based anywhere in the world and which the Investment Manager believes are undervalued. Up to 30% of the Fund may be invested in other assets ...
Add Yahoo as a preferred source to see more of our stories on Google. AC-101 was developed using the company’s platform focused on regulatory cell death and inflammation Accro Bioscience (Accro Bio) ...
AC-101 was developed using the company’s platform focused on regulatory cell death and inflammation, intended for moderate-to-severe UC. Credit: Jo Panuwat D / Shutterstock.com. Accro Bioscience ...
Accro Bioscience has dosed its first patient in a Phase IIb trial of AC-101, a selective RIPK2 inhibitor, for moderate-to-severe ulcerative colitis, setting up a 12-week clinical remission readout ...
NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ -- Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune ...
AI success depends on whether enterprise data is ready, reachable, and close enough to the workloads that need it. In this eSpeaks episode, Dell Technologies’ Vrashank Jain explains why fragmented ...
Selective RIPK2 inhibitor gains regulatory momentum in China following US FDA Rare Pediatric Disease designation, while clinical development also advances in ulcerative colitis. Accro Bioscience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results